EP3820859B1 - Inhibiteurs de l'histone désacétylase - Google Patents

Inhibiteurs de l'histone désacétylase Download PDF

Info

Publication number
EP3820859B1
EP3820859B1 EP19746301.1A EP19746301A EP3820859B1 EP 3820859 B1 EP3820859 B1 EP 3820859B1 EP 19746301 A EP19746301 A EP 19746301A EP 3820859 B1 EP3820859 B1 EP 3820859B1
Authority
EP
European Patent Office
Prior art keywords
mmol
compound
disease
disorder
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19746301.1A
Other languages
German (de)
English (en)
Other versions
EP3820859C0 (fr
EP3820859A1 (fr
Inventor
Nathan Oliver Fuller
John A. Lowe, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of EP3820859A1 publication Critical patent/EP3820859A1/fr
Application granted granted Critical
Publication of EP3820859C0 publication Critical patent/EP3820859C0/fr
Publication of EP3820859B1 publication Critical patent/EP3820859B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • HDAC histone deacetylases
  • HAT histone acetyltransferase
  • HDAC histone deacetylases
  • Class I includes HDAC1, HDAC2, HDAC3, and HDAC8 and has homology to yeast RPD3.
  • HDAC4, HDAC5, HDAC7, and HDAC9 belong to class IIa and have homology to yeast.
  • HDAC6 and HDAC10 contain two catalytic sites and are classified as class IIb.
  • Class III (the sirtuins) includes SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
  • HDAC11 is another recently identified member of the HDAC family and has conserved residues in its catalytic center that are shared by both class I and class II deacetylases and is sometimes placed in class IV.
  • HDACs have been shown to be powerful negative regulators of long-term memory processes.
  • Nonspecific HDAC inhibitors enhance synaptic plasticity as well as long-term memory ( Levenson et al., 2004, J. Biol. Chem. 279:40545-40559 ; Lattal et al., 2007, Behav Neurosci 121:1125-1131 ; Vecsey et al., 2007, J. Neurosci 27:6128 ; Bredy, 2008, Learn Mem 15:460-467 ; Guan et al., 2009, Nature 459:55-60 ; Malvaez et al., 2010, Biol.
  • HDAC inhibition can transform a learning event that does not lead to long-term memory into a learning event that does result in significant long-term memory ( Stefanko et al., 2009, Proc. Natl. Acad. Sci. USA 106:9447-9452 ). Furthermore, HDAC inhibition can also generate a form of long-term memory that persists beyond the point at which normal memory fails.
  • HDAC inhibitors have been shown to ameliorate cognitive deficits in genetic models of Alzheimer's disease ( Fischer et al., 2007, Nature 447:178-182 ; Kilgore et al., 2010, Neuropsychopharmacology 35:870-880 ). These demonstrations suggest that modulating memory via HDAC inhibition has considerable therapeutic potential for many memory and cognitive disorders.
  • HDAC1, HDAC2, HDAC3, HDAC8 nonspecific HDAC inhibitors, such as sodium butyrate, inhibit class I HDACs (HDAC1, HDAC2, HDAC3, HDAC8) with little effect on the class IIa HDAC family members (HDAC4, HDAC5, HDAC7, HDAC9).
  • HDAC4, HDAC5, HDAC7, HDAC9 class IIa HDAC family members
  • HDAC4, HDAC5, HDAC7, HDAC9 class IIa HDAC family members
  • HDAC2 knockout mice exhibited increased synaptic density, increased synaptic plasticity and increased dendritic density in neurons. These HDAC2 deficient mice also exhibited enhanced learning and memory in a battery of learning behavioral paradigms. This work demonstrates that HDAC2 is a key regulator of synaptogenesis and synaptic plasticity. Additionally, Guan et al. showed that chronic treatment of mice with SAHA (an HDAC 1,2,3,6, 8 inhibitor) reproduced the effects seen in the HDAC2 deficient mice and recused the cognitive impairment in the HDAC2 overexpression mice.
  • SAHA an HDAC 1,2,3,6, 8 inhibitor
  • HDAC2 selective neurotrophic kinase inhibitors
  • WO 2017/007756 describes compounds that are inhibitors of HDAC2.
  • HDAC histone deacetylases
  • Certain compounds described herein have an increase in inhibitory activity in a cell lysate assay over direct comparators. For example, it was found that introducing aromatic substitutions at the 3-positon of the pyrrolidine (e.g., the phenyl and heteroaryl variables for R 1 ) led to a significant increase in potency in an HDAC2 SH-SY5Y cell lysate assay when compared with counterparts possessing non-aromatic substitution at the pyrrolidine-3-position. See e.g., Table 4, where Compounds 19 and 20, each having an aromatic pyrimidinyl at R 1 , have greater potency then the non-cyclic, non-aromatic, Comparators A-C.
  • a hyphen designates the point of attachment of that group to the variable to which it is defined.
  • -(C 1 -C 4 )alkylheteroaryl and -(C 1 -C 4 )alkylheterocyclyl means that the point of attachment occurs on the (C 1 -C 4 )alkyl residue.
  • halo and halogen refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), and iodine (iodo, -I).
  • alkyl when used alone or as part of a larger moiety, such as “haloalkyl”, means a saturated straight-chain or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group typically has 1-6 carbon atoms, i.e., (C 1 -C 6 )alkyl.
  • haloalkyl includes mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, bromine, and iodine.
  • Alkoxy means an alkyl radical attached through an oxygen linking atom, represented by -O-alkyl.
  • (C 1 -C 4 )alkoxy includes methoxy, ethoxy, proproxy, and butoxy.
  • Haloalkoxy is a haloalkyl group which is attached to another moiety via an oxygen atom such as, e.g., but are not limited to -OCHF 2 or -OCF 3 .
  • heteroaryl refers to a 5- to 12-membered (e.g., 5- or 6-membered) aromatic radical containing 1-4 heteroatoms selected from N, O, and S.
  • a heteroaryl group may be mono- or bi-cyclic.
  • Monocyclic heteroaryl includes, for example, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc.
  • Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings.
  • Nonlimiting examples include indolyl, imidazopyridinyl, benzooxazolyl, benzooxodiazolyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl, thienopyridinyl, thienopyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. It will be understood that when specified, optional substituents on a heteroaryl group may be present on any substitutable position and, include, e.g., the position at which the heteroaryl is attached.
  • heterocyclyl means a 4- to 12-membered (e.g., 4- to 6-membered) saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
  • a heterocyclyl ring can be mononcyclic, bicyclic (e.g., a bridged, fused, or spiro bicyclic ring), or tricyclic.
  • a heterocyclyl ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, terahydropyranyl, pyrrolidinyl, pyridinonyl, pyrrolidonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, oxetanyl, azetidinyl and tetrahydropyrimidinyl.
  • heterocyclyl also includes, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical or aryl or heteroaryl ring, such as for example, tetrahydronaphthyridine, indolinone, dihydropyrrolotriazole, imidazopyrimidine, quinolinone, dioxaspirodecane.
  • optional substituents on a heterocyclyl group may be present on any substitutable position and, include, e.g., the position at which the heterocyclyl is attached (e.g., in the case of an optionally substituted heterocyclyl or heterocyclyl which is optionally substituted).
  • fused refers to two rings that share two adjacent ring atoms with one another.
  • spiro refers to two rings that shares one ring atom (e.g., carbon).
  • bridged refers to two rings that share three ring atoms with one another.
  • Enantiomers are one type of stereoisomer that can arise from a chiral center or chiral centers. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom or carbon atoms that acts as a chiral center(s).
  • R and S represent the absolute configuration of substituents around one or more chiral carbon atoms, where each chiral center is assigned the prefix "R” or "S” according to whether the chiral center configuration is right- (clockwise rotation) or left-handed (counter clockwise rotation). If the turn is clockwise or right-handed about a chiral carbon, the designation is "R” for rectus. If the turn is counter clockwise or left-handed about a chiral carbon, the designation is "S” for sinister.
  • the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
  • the structure includes either configuration at the chiral center or, alternatively, any mixture of configurations at the chiral center stereoisomers.
  • Racemate or “racemic mixture” means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity, i.e., they do not rotate the plane of polarized light.
  • the terms "subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g ., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
  • the subject is a human in need of treatment.
  • Pharmaceutically acceptable salts as well as the neutral forms of the compounds described herein are included.
  • the salts of the compounds refer to non-toxic "pharmaceutically acceptable salts.”
  • Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
  • Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
  • pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol
  • treatment refers to reversing, alleviating, reducing the likelihood of developing, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed, i.e ., therapeutic treatment.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g ., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • an effective amount or “therapeutically effective amount” includes an amount of a compound described herein that will elicit a biological or medical response of a subject e.g., between 0.01 - 100 mg/kg body weight/day of the provided compound, such as e.g., 0.1 - 100 mg/kg body weight/day.
  • R 1 in any one of Formula VI or VII is phenyl or 5- to 6-membered monocyclic heteroaryl, each of which is optionally substituted with one or more groups selected from R c , wherein the remaining variables are as described above for Formula VI or VII.
  • R 1 in any one of Formula VI, or VII is phenyl, pyridinyl, pyrazinyl, pyridazinyl, or pyrimidinyl, each of which is optionally substituted with 1 to 2 groups selected from R c , wherein the remaining variables are as described above for Formula VI or VII.
  • R 1 in any one of Formula VI or VII is thiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, or oxazolyl, each of which is optionally substituted with 1 to 2 groups selected from R c , wherein the remaining variables are as described above for Formula VI or VII.
  • R c in any one of Formula VI or VII is halo, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkylO(C 1 -C 4 )alkyl, wherein the remaining variables are as described above for Formula VI or VII.
  • R c in any one of Formula VI or VII is fluoro, methyl, or CH 2 OCH 3 , wherein the remaining variables are as described above for Formula VI or VII.
  • R c in any one of Formula VI or VII is halo, halo(C 1 -C 4 )alkyl, or (C 1 -C 4 )alkyl, wherein the remaining variables are as described above for Formula VI or VII.
  • R c in any one of Formula VI or VII is fluoro, methyl, or CHF 2 , wherein the remaining variables are as described above for Formula VI or VII.
  • a compound as described below in the Exemplification section provided is a compound as described below in the Exemplification section.
  • Pharmaceutically acceptable salts and free forms of the exemplified compounds are included.
  • references to methods of treatment used herein are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis).
  • the compounds and compositions described herein are useful in treating conditions associated with the activity of HDAC. Such conditions include for example, those described below.
  • CNS central nervous system
  • the provided compounds and compositions may be useful in treating a neurological disorder.
  • neurological disorders include: (i) chronic neurodegenerative diseases such as familial and sporadic amyotrophic lateral sclerosis (FALS and ALS, respectively), familial and sporadic Parkinson's disease, Huntington's disease, familial and sporadic Alzheimer's disease, multiple sclerosis, muscular dystrophy, olivopontocerebellar atrophy, multiple system atrophy, Wilson's disease, progressive supranuclear palsy, diffuse Lewy body disease, fronto-temporal lobar degeneration (FTLD), corticodentatonigral degeneration, progressive familial myoclonic epilepsy, strionigral degeneration, torsion dystonia, familial tremor, Down's Syndrome, Gilles de la Tourette syndrome, Hallervorden-Spatz disease, diabetic peripheral neuropathy, dementia pugilistica, AIDS Dementia, age related dementia, age associated memory impairment, and amyloidosis-related neurodegenerative diseases such as those caused by the prion protein (F
  • Neurological disorders affecting sensory neurons include Friedreich's ataxia, diabetes, peripheral neuropathy, and retinal neuronal degeneration. Other neurological disorders include nerve injury or trauma associated with spinal cord injury. Neurological disorders of limbic and cortical systems include cerebral amyloidosis, Pick's atrophy, and Rett syndrome. In another aspect, neurological disorders include disorders of mood, such as affective disorders and anxiety; disorders of social behavior, such as character defects and personality disorders; disorders of learning, memory, and intelligence, such as mental retardation and dementia.
  • the disclosed compounds and compositions may be useful in treating schizophrenia, delirium, attention deficit disorder (ADD), schizoaffective disorder, Alzheimer's disease, Rubinstein-Taybi syndrome, depression, mania, attention deficit disorders, drug addiction, dementia, agitation, apathy, anxiety, psychoses, personality disorders, bipolar disorders, unipolar affective disorder, obsessive-compulsive disorders, eating disorders, post-traumatic stress disorders, irritability, adolescent conduct disorder and disinhibition.
  • ADD attention deficit disorder
  • schizoaffective disorder Alzheimer's disease
  • Rubinstein-Taybi syndrome depression
  • mania attention deficit disorders
  • drug addiction dementia
  • dementia agitation
  • apathy anxiety, psychoses, personality disorders, bipolar disorders, unipolar affective disorder, obsessive-compulsive disorders, eating disorders, post-traumatic stress disorders, irritability, adolescent conduct disorder and disinhibition.
  • HATs histone acetyltransferases
  • HDACs histone deacetylases
  • the provided compounds and compositions may be useful for promoting cognitive function and enhancing learning and memory formation.
  • the compounds and compositions described herein may also be used for treating fungal diseases or infections.
  • the compounds and compositions described herein may be used for treating inflammatory diseases such as stroke, rheumatoid arthritis, lupus erythematosus, ulcerative colitis and traumatic brain injuries ( Leoni et al., PNAS, 99(5); 2995-3000(2002 ); Suuronen et al. J. Neurochem. 87; 407-416 (2003 ) and Drug Discovery Today, 10: 197-204 (2005 ).
  • inflammatory diseases such as stroke, rheumatoid arthritis, lupus erythematosus, ulcerative colitis and traumatic brain injuries
  • the compounds and compositions described herein may be used for treating a cancer caused by the proliferation of neoplastic cells.
  • cancers include e.g., solid tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphomas and the like.
  • cancers that may be treated by the compounds and compositions described herein include, but are not limited to: cardiac cancer, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, nervous system cancer, gynecological cancer, hematologic cancer, skin cancer, and adrenal gland cancer.
  • the compounds and compositions described herein are useful in treating cardiac cancers selected from sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma.
  • sarcoma angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma
  • myxoma rhabdomyoma
  • fibroma fibroma
  • lipoma lipoma
  • teratoma teratoma
  • the compounds and compositions described herein are useful in treating a lung cancer selected from bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma.
  • a lung cancer selected from bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma.
  • the compounds and compositions described herein are useful in treating a gastrointestinal cancer selected from esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), and large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma).
  • esophagus squamous cell carcinoma, adenocarcinoma, lei
  • the compounds and compositions described herein are useful in treating a genitourinary tract cancer selected from kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
  • kidney adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia
  • bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma,
  • the compounds and compositions described herein are useful in treating a liver cancer selected from hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
  • hepatoma hepatocellular carcinoma
  • cholangiocarcinoma hepatoblastoma
  • angiosarcoma hepatocellular adenoma
  • hemangioma hemangioma
  • the compounds described herein relate to treating, a bone cancer selected from osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
  • osteogenic sarcoma osteogenic sarcoma
  • fibrosarcoma malignant fibrous histiocytoma
  • chondrosarcoma chondrosarcoma
  • Ewing's sarcoma malignant lymphoma
  • multiple myeloma malignant giant cell tumor chordoma
  • osteochondroma o
  • the compounds and compositions described herein are useful in treating a nervous system cancer selected from skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma).
  • skull osteoma, hemangioma, granuloma, xanthoma, osteitis deformans
  • meninges meningioma, meningio
  • the compounds and compositions described herein are useful in treating a gynecological cancer selected from uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).
  • a gynecological cancer selected from uterus (endometrial carcinoma), cervix (cer
  • the compounds and compositions described herein are useful in treating a skin cancer selected from malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and psoriasis.
  • the compounds and compositions described herein are useful in treating an adrenal gland cancer selected from neuroblastoma.
  • the compounds and compositions described herein are useful in treating cancers that include, but are not limited to: leukemias including acute leukemias and chronic leukemias such as acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) and Hairy Cell Leukemia; lymphomas such as cutaneous T-cell lymphomas (CTCL), noncutaneous peripheral T-cell lymphomas, lymphomas associated with human T-cell lymphotrophic virus (HTLV) such as adult T-cell leukemia/lymphoma (ATLL), Hodgkin's disease and non-Hodgkin's lymphomas, large-cell lymphomas, diffuse large B-cell lymphoma (DLBCL); Burkitt's lymphoma; mesothelioma, primary central nervous system (CNS) lymphoma; multiple myeloma; childhood solid tumors such as brain tumor
  • ALL
  • provided herein is a method of treating a subject suffering from a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, psychiatric disorders, and neoplastic disease, comprising administering to the subject an effective amount a compound described herein, or a pharmaceutically acceptable salt thereof, or the composition comprising a compound described herein.
  • Also provided herein is a method of treating a subject suffering from (a) a cognitive function disorder or impairment associated with Alzheimer's disease, posterior cortical atrophy, normal-pressure hydrocephalus, Huntington's disease, seizure induced memory loss, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, depression, Fragile X, Lewy body dementia, vascular dementia, vascular cognitive impairment (VCI), Binswanger's Disease, fronto-temporal lobar degeneration (FTLD), ADHD, dyslexia, major depressive disorder, bipolar disorder and social, cognitive and learning disorders associated with autism, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), multiple sclerosis (MS), attention deficit disorder, anxiety disorder, conditioned fear response, panic disorder, obsessive compulsive disorder, posttraumatic stress disorder (PTSD), phobia, social anxiety disorder, substance dependence recovery, Age Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), ataxia, Parkinson's disease, or Parkinson's disease dementia
  • a method of treating a subject suffering from Alzheimer's disease, Huntington's disease, frontotemporal dementia, Friedreich's ataxia, post-traumatic stress disorder (PTSD), Parkinson's disease, or substance dependence recovery comprising administering to the subject an effective amount a compound described herein, or a pharmaceutically acceptable salt thereof, or the composition comprising a compound described herein.
  • Subjects may also be selected to be suffering from one or more of the described conditions prior to treatment with a compound described herein, or a pharmaceutically acceptable salt thereof, or a provided composition.
  • compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. These compositions can be used to treat one or more of the conditions described above.
  • compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
  • the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
  • Compound 20 11 mg, 47 %, a light yellow solid.
  • Compound 46 100 mg, 63%, a lighty yellow solid.
  • 2007-B Synthesis of 2007-B. To a solution of 2007-A (70 mg, 0.26 mmol) in DCM (6 mL) was added TFA (2 mL) dropwise. The reaction mixture was stirred at room temperature for 1 h, whereupon the solvent was removed in vacuo to give 2007-B as a crude product which was used directly in the next step without further purification.
  • Compound 45 was synthesized in a similar manner as 29 by using 2-(5-fluorothiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a reagent.
  • Compound 33 was synthesized in a similar manner as 31 by using tert -butyl 3-iodopyrrolidine-1-carboxylate and 2-bromo-5-methylpyrimidine as reagents.
  • Compound 48 was synthesized in a similar manner as 31 by using tert -butyl 3-iodopyrrolidine-1-carboxylate, 2-bromopyrimidine and 2-fluorophenylboronic acid as reagents.
  • Compound 48 38 mg, 41%, a light yellow solid.
  • Compound 37 was synthesized in a similar manner as 32 by using the appropriately substituted aryl bromide reagent. Compound 37. 65 mg, 58%, a light yellow solid.
  • Compound 42 was synthesized in a similar manner as 41 by using methyl magnesium bromide and appropriately substituted boronic acid reagent.
  • reaction mixture was cooled to -78 °C, and another portion of n -BuLi (100 mL, 250 mmol) was added dropwise at -78 °C and stirred at -78 °C for 1 h.
  • 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (46.5 g, 250 mmol) in THF (200 mL) was added into above mixture dropwise at -78 °C, and the reaction mixture was allowed to warm to room temperature and stirred for 16 h.
  • Compound 49 was synthesized in a similar manner as 39 and 40 by using the appropriately substituted boronic acid and aryl bromide reagents. Compound 49. 30 mg, 23%, a yellow solid.
  • 8E1 396 397 ⁇ 8.79(t, J 4.8 Hz, 2H), 8.33 (s, 1H), 7.98 - 7.91 (m, 1H), 7.42 - 7.37 (m, 2H), 7.31-7.25 (m, 1H), 7.17 - 7.13 (m, 2H), 5.22 (s, 2H), 3.90 - 3.87 (m, 1H), 3.76 - 3.75 (m, 2H), 3.65 - 3.60 (m, 1H), 3.56 - 3.49 (m, 1H), 2.37 - 2.33 (m, 1H), 2.28 - 2.22 (m, 1H).
  • HDAC2 and HDAC1 Enzymatic Assay (HDAC2 and HDAC1 IC50 data)
  • the following describes an assay protocol for measuring the deacetylation of a peptide substrate by HDAC2 or HDAC1.
  • HDAC protein composition and respective substrate peptides are summarized below.
  • Assay name Expression Construct Regulatory subunit Substrate peptide HDAC1 Full length Human HDAC1 with C-terminal His-tag and C-terminal FLAG-tag, expressed in baculovirus expression system. None FAM-TSRHK(Ac)KL-NH2 HDAC2 Full length Human HDAC2 with C-terminal FLAG-tag, expressed in baculovirus expression system. None FAM-TSRHK(Ac)KL-NH2
  • HDAC reactions are assembled in 384 well plates (Greiner) in a total volume of 20 ⁇ L as following: HDAC proteins are pre-diluted in the assay buffer comprising: 100mM HEPES, pH 7.5, 0.1% BSA, 0.01% Triton X-100, 25mM KC1 and dispensed into 384 well plate (10uL per well).
  • Test compounds are serially pre-diluted in DMSO and added to the protein samples by acoustic dispensing (Labcyte Echo). Concentration of DMSO is equalized to 1% in all samples.
  • Control samples (0%-inhibition in the absence of inhibitor, DMSO only) and 100%-inhibition (in the absence of enzyme) are assembled in replicates of four and used to calculate the %-inhibition in the presence of compounds.
  • compounds can be pre-incubated with enzyme if desired.
  • the reactions are initiated by addition of 10uL of the FAM-labeled substrate peptide pre-diluted in the same assay buffer. Final concentration of substrate peptide is 1uM (HDAC1-2). The reactions are allowed to proceed at room temperature. Following incubation, the reactions are quenched by addition of 50 ⁇ L of termination buffer (100 mM HEPES, pH7.5, 0.01% Triton X-100, 0.1% SDS). Terminated plates are analyzed on a microfluidic electrophoresis instrument (Caliper LabChip ® 3000, Caliper Life Sciences/Perkin Elmer) which enables electrophoretic separation of de-acetylated product from acetylated substrate.
  • termination buffer 100 mM HEPES, pH7.5, 0.01% Triton X-100, 0.1% SDS
  • a change in the relative intensity of the peptide substrate and product is the parameter measured.
  • Activity in each test sample is determined as the product to sum ratio (PSR): P/(S+P), where P is the peak height of the product, and S is the peak height of the substrate.
  • IC50 of compounds 50%-inhibition
  • the %-inh data (P inh versus compound concentration) are fit by a 4 parameter sigmoid dose-response model using XLfit software (IDBS).
  • SH-SY5Y cells (Sigma) were cultured in Eagle's Modified Essential Medium supplemented with 10% fetal bovine serum and pen/strep. Twenty-four hours prior to compound dosing 20 uL of cells were plated in white 384 well plates at a density of 1,500 cells/well. Compounds were serially diluted in neat DMSO and then diluted 1:100 v/v into media without FBS and mixed. Media was removed from the plated cells and the diluted compounds in serum free media (1% v/v final DMSO) were added and incubated at 37 ° C for five hours.
  • Table 4 shows direct comparison of the activity levels between certain compounds possessing non-aromatic substitution at the pyrrolidine-3-position and inventive compounds possessing aromatic substitution at the 3-position of the pyrrolidinyl motif (i.e., R 1 with or without spacer group X).
  • R 1 with or without spacer group X
  • an increase in potency in the HDAC2 SH-SY5Y cell lysate assay results when the non-cyclic, non-aromatic substituents for R 1 in Comparators A-C are replaced with the aromatic pyrimidinyl in Compounds 19 and 20.
  • a similar trend is seen for other compounds in Table 4.
  • Compound 20 with a 5-F-pyrimidine directly linked to the 3-position is >2-fold more potent than Comparator A.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (14)

  1. Composé de formule VI ou VII :
    Figure imgb0146
     ou sel pharmaceutiquement acceptable de celui-ci, dans lequel
    R1 est un phényle ou un hétéroaryle, chacun étant éventuellement substitué par 1 à 3 groupes choisis parmi Rc ;
    R3 est un hydrogène ou un fluoro ;
    R4 est un fluor ; et
    Rc est un halogène, un alkyle en C1-C4, un halogénoalkyle en C1-C4, un alcoxy en C1-C4, un halogénoalcoxy en C1-C4, un (alkyl en C1-C4)O(alkyle en C1-C4), un (alkyl en C1-C4)NH(alkyle en C1-C4), un (alkyl en C1-C4)NH (alkyle en C1-C4)2, un -(alkyl en C1-C4)hétéroaryle ou un - (alkyl en C1-C4)hétérocyclyle, dans lequel lesdits hétéroaryle et hétérocyclyle sont chacun éventuellement et indépendamment substitués par 1 à 3 groupes choisis parmi un alkyle en C1-C4, un halogénoalkyle en C1-C4, un alcoxy en C1-C4 et un halogéno ; dans lequel l'hétéroaryle représente un radical aromatique de 5 à 12 chaînons contenant 1 à 4 hétéroatomes choisis parmi N, O et S ; et
    l'hétérocyclyle représente un cycle hétérocyclique saturé ou partiellement insaturé de 4 à 12 chaînons contenant 1 à 4 hétéroatomes indépendamment choisis parmi N, O et S.
  2. Composé selon la revendication 1, dans lequel R1 est un phényle ou un hétéroaryle monocyclique à 5 ou 6 chaînons, dont chacun est éventuellement substitué par un ou plusieurs groupes choisis parmi Rc.
  3. Composé selon la revendication 1 ou 2, dans lequel R1 est un phényle, un pyridinyle, un pyrazinyle, un pyridazinyle ou un pyrimidinyle, dont chacun est éventuellement substitué par 1 ou 2 groupes choisis parmi Rc.
  4. Composé selon l'une quelconque des revendications 1 à 3, dans lequel R1 est un thiazolyle, un thiadiazolyle, un imidazolyle, un pyrazolyle ou un oxazolyle, dont chacun est éventuellement substitué par 1 ou 2 groupes choisis parmi Rc.
  5. Composé selon l'une quelconque des revendications 1 à 4, dans lequel Rc est un halogène, un alkyle en C1-C4 ou un (alkyl en C1-C4)O(alkyle en C1-C4).
  6. Composé selon l'une des revendications 1 à 5, dans lequel Rc est un fluoro, un méthyle ou CH2OCH3.
  7. Composé selon l'une quelconque des revendications 1 à 6, dans lequel Rc est un halogène, un halogénoalkyle en C1-C4 ou un alkyle en C1-C4.
  8. Composé selon l'une des revendications 1 à 7, dans lequel Rc est un fluoro, un méthyle, ou CHF2.
  9. Composé selon la revendication 1, dans lequel le composé est choisi parmi
    Figure imgb0147
    Figure imgb0148
    Figure imgb0149
    Figure imgb0150
    Figure imgb0151
    Figure imgb0152
    Figure imgb0153
    Figure imgb0154
    Figure imgb0155
    Figure imgb0156
    Figure imgb0157
    Figure imgb0158
    Figure imgb0159
    Figure imgb0160
    Figure imgb0161
    Figure imgb0162
    Figure imgb0163
    Figure imgb0164
     ; et
    Figure imgb0165
     ou un sel pharmaceutiquement acceptable de celui-ci.
  10. Composition comprenant un composé selon l'une quelconque des revendications 1 à 9, ou un sel pharmaceutiquement acceptable de celui-ci ; et un véhicule pharmaceutiquement acceptable.
  11. Composé selon l'une quelconque des revendications 1 à 9, ou sel pharmaceutiquement acceptable de celui-ci, ou composition selon la revendication 10, destiné à être utilisé dans le traitement d'une pathologie choisie parmi un trouble neurologique, un trouble ou une déficience de la mémoire ou de la fonction cognitive, un trouble d'apprentissage par extinction, une maladie ou une infection fongique, une maladie inflammatoire, une maladie hématologique, des troubles psychiatriques et une maladie néoplasique.
  12. Composé ou composition destiné à être utilisé selon la revendication 11, dans lequel la pathologie est :
    a. un trouble ou une déficience de la fonction cognitive associé à la maladie d'Alzheimer, à l'atrophie corticale postérieure, à l'hydrocéphalie à pression normale, à la maladie de Huntington, à la perte de mémoire induite par des convulsions, à la schizophrénie, au syndrome de Rubinstein Taybi, au syndrome de Rett, à la dépression, au X fragile, à la démence à corps de Lewy, à l'accident vasculaire cérébral, à la démence vasculaire, à la déficience cognitive vasculaire (VCI), à la maladie de Binswanger, à la dégénérescence lobaire fronto-temporale (DLFT), au TDAH, à la dyslexie, au trouble dépressif majeur, au trouble bipolaire et aux troubles sociaux, cognitifs et d'apprentissage associés à l'autisme, au traumatisme crânien (TCC), à l'encéphalopathie traumatique chronique (CTE), à la sclérose en plaques (SEP), au trouble déficitaire de l'attention, au trouble anxieux, à la réaction de peur conditionnée, au trouble de panique, au trouble obsessionnel compulsif, au trouble de stress post-traumatique (SSPT), à la phobie, au trouble d'anxiété sociale, au rétablissement de la dépendance à une substance, aux troubles de la mémoire associés à l'âge (AAMI), au déclin cognitif lié à l'âge (ARCD), à l'ataxie, à la maladie de Parkinson ou à la démence liée à la maladie de Parkinson ; ou
    b. une maladie hématologique choisie parmi la leucémie myéloïde aiguë, la leucémie promyélocytaire aiguë, la leucémie lymphoblastique aiguë, la leucémie myéloïde chronique, les syndromes myélodysplasiques et l'anémie falciforme ; ou
    c. une maladie néoplasique ; ou
    d. un trouble d'extinction de l'apprentissage choisi parmi l'extinction de la peur et le trouble de stress post-traumatique ; ou
    e. une perte auditive ou un trouble auditif ; ou
    f. des maladies fibrotiques, telles que la fibrose pulmonaire, la fibrose rénale, la fibrose cardiaque et la sclérodermie ; ou
    g. des douleurs osseuses chez les patients atteints de cancer ; ou
    h. une douleur neuropathique.
  13. Composé ou composition destiné à être utilisé selon la revendication 12, dans lequel l'état est la maladie d'Alzheimer, la maladie de Huntington, la démence frontotemporale, l'ataxie de Friedreich, le trouble de stress post-traumatique (TSPT), la maladie de Parkinson ou le rétablissement d'une dépendance à une substance.
  14. Composé ou composition destiné à être utilisé selon la revendication 11, dans lequel la pathologie est choisie parmi la maladie d'Alzheimer, la maladie de Huntington, la dégénérescence lobaire fronto-temporale, l'ataxie de Friedreich, le trouble de stress post-traumatique, la maladie de Parkinson, la démence due à la maladie de Parkinson, la guérison d'une dépendance à une substance, le trouble ou la déficience de la mémoire ou de la fonction cognitive, le trouble neurologique avec pathologie synaptique, le trouble de la distinction des apprentissages, les troubles psychiatriques, la fonction ou la déficience cognitive associée à la maladie d'Alzheimer, la démence à corps de Lewy, la schizophrénie, le syndrome de Rubinstein Taybi, le syndrome de Rett, le X fragile, la sclérose en plaques, les troubles de la mémoire liés à l'âge, le déclin cognitif lié à l'âge et les troubles sociaux, cognitifs et d'apprentissage liés à l'autisme.
EP19746301.1A 2018-07-13 2019-07-12 Inhibiteurs de l'histone désacétylase Active EP3820859B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697498P 2018-07-13 2018-07-13
PCT/US2019/041592 WO2020014605A1 (fr) 2018-07-13 2019-07-12 Inhibiteurs de l'histone désacétylase

Publications (3)

Publication Number Publication Date
EP3820859A1 EP3820859A1 (fr) 2021-05-19
EP3820859C0 EP3820859C0 (fr) 2024-03-20
EP3820859B1 true EP3820859B1 (fr) 2024-03-20

Family

ID=67480370

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19746301.1A Active EP3820859B1 (fr) 2018-07-13 2019-07-12 Inhibiteurs de l'histone désacétylase

Country Status (15)

Country Link
US (1) US20210276978A1 (fr)
EP (1) EP3820859B1 (fr)
JP (2) JP7414820B2 (fr)
KR (1) KR20210031704A (fr)
CN (1) CN112424184A (fr)
AR (1) AR115768A1 (fr)
AU (1) AU2019300036A1 (fr)
CA (1) CA3106355A1 (fr)
EA (1) EA202190077A1 (fr)
IL (2) IL279940B2 (fr)
MA (1) MA53129A (fr)
MX (1) MX2021000468A (fr)
SG (1) SG11202012916WA (fr)
TW (1) TWI809146B (fr)
WO (1) WO2020014605A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
MD3664802T2 (ro) 2017-08-07 2022-07-31 Alkermes Inc Inhibitori biciclici ai deacetilazei histonei
CA3240229A1 (fr) 2021-12-03 2023-06-08 Tango Therapeutics, Inc. Nouveaux inhibiteurs de hdac et leur utilisation therapeutique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008271170A1 (en) * 2007-06-27 2009-01-08 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
JP6240063B2 (ja) * 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2016018795A1 (fr) * 2014-07-28 2016-02-04 The General Hospital Corporation Inhibiteurs d'histone désacétylase
RS62639B1 (sr) * 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3043618A1 (fr) * 2016-11-23 2018-05-31 Regenacy Pharmaceuticals, Llc Derives piperazine en tant qu'inhibiteurs selectifs de hdac1,2

Also Published As

Publication number Publication date
JP7414820B2 (ja) 2024-01-16
AU2019300036A1 (en) 2021-01-14
IL279940B2 (en) 2024-06-01
IL279940B1 (en) 2024-02-01
JP2021531336A (ja) 2021-11-18
SG11202012916WA (en) 2021-01-28
MX2021000468A (es) 2021-06-23
MA53129A (fr) 2021-05-19
KR20210031704A (ko) 2021-03-22
TW202019903A (zh) 2020-06-01
CA3106355A1 (fr) 2020-01-16
CN112424184A (zh) 2021-02-26
AR115768A1 (es) 2021-02-24
IL309951A (en) 2024-03-01
WO2020014605A1 (fr) 2020-01-16
EA202190077A1 (ru) 2021-08-30
TWI809146B (zh) 2023-07-21
EP3820859C0 (fr) 2024-03-20
EP3820859A1 (fr) 2021-05-19
IL279940A (en) 2021-03-01
US20210276978A1 (en) 2021-09-09
JP2024038202A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
EP3820859B1 (fr) Inhibiteurs de l'histone désacétylase
EP3820863A1 (fr) Inhibiteurs bicycliques de l'histone désacétylase
US11225479B2 (en) Bicyclic inhibitors of histone deacetylase
WO1999050264A1 (fr) Derives de quinazoline
EP3664802B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
WO2020117877A1 (fr) Composés, compositions et procédés d'utilisation associés
EA043804B1 (ru) Ингибиторы гистондеацетилазы
EA044565B1 (ru) Бициклические ингибиторы гистондеацетилазы
KR20130115696A (ko) 신경보호제로서의 유레아 유도체

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052502

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221031

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231010

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019048616

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240416

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240320

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240620

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240620

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240320

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240720

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240320